629 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Outlook Wealth Advisors LLC

Outlook Wealth Advisors LLC purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 1st quarter, Holdings Channel.com reports. The fund purchased 629 shares of the pharmaceutical company’s stock, valued at approximately $263,000.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Vertex Pharmaceuticals by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 22,282,180 shares of the pharmaceutical company’s stock worth $9,066,396,000 after buying an additional 298,824 shares during the period. Capital World Investors increased its stake in shares of Vertex Pharmaceuticals by 21.3% during the 4th quarter. Capital World Investors now owns 21,805,770 shares of the pharmaceutical company’s stock valued at $8,872,586,000 after acquiring an additional 3,824,103 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of Vertex Pharmaceuticals by 3.9% during the 4th quarter. Jennison Associates LLC now owns 3,944,913 shares of the pharmaceutical company’s stock worth $1,605,146,000 after acquiring an additional 147,248 shares during the period. Capital Research Global Investors boosted its position in shares of Vertex Pharmaceuticals by 5.8% in the fourth quarter. Capital Research Global Investors now owns 3,567,664 shares of the pharmaceutical company’s stock worth $1,451,647,000 after acquiring an additional 195,080 shares during the last quarter. Finally, Norges Bank purchased a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $1,237,877,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 4,295 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the transaction, the chief operating officer now owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ourania Tatsis sold 354 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The disclosure for this sale can be found here. Insiders have sold a total of 12,381 shares of company stock valued at $5,203,249 in the last quarter. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ:VRTX traded down $0.22 during midday trading on Friday, reaching $397.48. The company had a trading volume of 682,467 shares, compared to its average volume of 909,553. Vertex Pharmaceuticals Incorporated has a one year low of $320.01 and a one year high of $448.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. The stock has a market capitalization of $102.73 billion, a P/E ratio of 28.62, a PEG ratio of 1.87 and a beta of 0.35. The stock’s fifty day moving average price is $411.60 and its 200-day moving average price is $398.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. The business had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same quarter in the prior year, the business posted $3.33 EPS. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on VRTX shares. HC Wainwright lifted their price target on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $440.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 20th. Guggenheim raised their price objective on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Barclays boosted their target price on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Finally, Wells Fargo & Company raised their price target on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.